Salarius Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell
July 29, 2019 09:02 ET
|
Salarius Pharmaceuticals
HOUSTON, July 29, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that President...
Salarius Pharmaceuticals Successfully Monetizes Legacy Consumer Product
July 24, 2019 16:05 ET
|
Salarius Pharmaceuticals
HOUSTON, July 24, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced it completed...
Salarius Pharmaceuticals Enrolls First Patient in a Phase 1 Clinical Study of its Novel Inhibitor Targeting Epigenetics in Patients with Advanced Solid Tumors
July 22, 2019 08:05 ET
|
Salarius Pharmaceuticals
HOUSTON, July 22, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced it has...
Salarius Pharmaceuticals Announces Closing of Strategic Merger with Flex Pharma
July 22, 2019 08:00 ET
|
Salarius Pharmaceuticals
HOUSTON, July 22, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that Salarius...